论文部分内容阅读
目的 探讨尼莫通预防和治疗蛛网膜下腔出血 (SAH)后脑血管痉挛 (CVS)引起的缺血性神经功能障碍的价值。方法 对照组 30例 ,入院后给予 6 -氨基已酸等抗纤溶药降低颅内压力及一般对症治疗。治疗组 6 0例 ,加用尼莫通每日 10mg ,用微量静脉输液泵 ,静脉序贯给药 5～ 10天 ,后口服至 2 1天的治疗方法。结果 2周内临床症状或体征缓解消失率尼莫通组高于对照组 ,P <0 .0 1,1月后致残、致死率对照组高于尼莫通组 ,P <0 .0 1。结论 尼莫通能降低SAH病人延迟性缺血性神经功能障碍的发生率和病死率 ,尼莫通治疗SAH有明显效果。
Objective To investigate the value of nimotop in the prevention and treatment of ischemic neurological dysfunction caused by cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). Methods Thirty patients in the control group were given antifibrinolytic drugs such as 6 - aminocaproic acid to reduce the intracranial pressure and the general symptomatic treatment. Treatment group 60 cases, plus nimotop daily 10mg, with a small amount of intravenous infusion pump intravenous administration of 5 to 10 days after oral administration to 21 days of treatment. Results In 2 weeks, the clinical symptoms or signs of disappearance of the disappearance rate of nimotop in the control group were higher than those in the control group, P <0.01, after 1 month, disabled, the lethality rate was higher in the control group than in the nimotop group, P <0.01 . Conclusion Nimotop can reduce the incidence of delayed ischemic neurological dysfunction and mortality in patients with SAH, nimodipine treatment of SAH have a significant effect.